US FDA Could soon approve Merck Cancer Immunotherapy Drug Pembrolizumab

August 26, 2014 2:17 AM

6 0

US FDA Could soon approve Merck Cancer Immunotherapy Drug Pembrolizumab

The U. S. FDA could soon approve melanoma drug pembrolizumab earlier than expected late October deadline. The drug would be first of its kind treatment using body’s immune system against melanoma. Merck & Co has submitted encouraging late-study results with its drug approval filing for the immuno-oncology drug.

The treatment improves the immune system to fight against the Programmed Death receptor (PD-1) protein. The new class of drugs is under development at AstraZeneca, Bristol-Myers Squibb and Roche Holding AG. The FDA approval for Merck & Co.’s pembrolizumab will offer boost to similar therapies for ot...

Read more

To category page

Loading...